KRAS and non-small cell lung carcinoma: Knockdown of EREG suppressed anchorage-dependent or anchorage-independent cell growth in NSCLC cells with both KRAS mutations and EREG overexpression [31], indicating the therapeutic potential of targeting EREG in KRAS-driven NSCLC.